Clinical-stage biotechnology company developing therapies for immune-mediated diseases of the eye.
Aldeyra Therapeutics, Inc. is a dynamic biotechnology company specializing in the development and commercialization of innovative medicines targeted at immune-mediated ocular and systemic diseases. At the forefront of its pipeline is reproxalap, a groundbreaking reactive aldehyde species (RASP) modulator currently advancing through Phase III clinical trials. This promising candidate aims to address dry eye diseases and allergic conjunctivitis, offering potential relief to a wide patient base.
In addition to reproxalap, Aldeyra Therapeutics is advancing ADX-629, a pioneering orally administered RASP modulator currently in Phase II clinical trials. This compound holds promise for treating diverse conditions such as psoriasis, asthma, and COVID-19, showcasing the company's commitment to addressing significant unmet medical needs across various therapeutic areas.
Further expanding its therapeutic portfolio, Aldeyra Therapeutics is developing ADX-2191, a dihydrofolate reductase inhibitor. This compound is progressing through Phase III trials for the prevention of proliferative vitreoretinopathy and Phase II trials for the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. These initiatives underscore the company's dedication to advancing treatments for complex ocular conditions.
Founded in 2004 and headquartered in Lexington, Massachusetts, Aldeyra Therapeutics was formerly known as Aldexa Therapeutics, Inc. The company rebranded in March 2014, reflecting its evolving focus and commitment to pioneering solutions in biotechnology aimed at enhancing patient outcomes globally.